Want to see ANTX full AI Analyst Report?
ANTX Stock Chart & Stats
$5.66
$0.00(0.00%)
At close: 4:00 PM EDT
$5.66
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.00 - $7.19
Previous CloseN/A
Volume128.47K
Average Volume (3M)292.89K
Market Cap
$127.17M
Enterprise Value$138.26M
Total Cash (Recent Filing)$78.39M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Nov 05, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend Yield17.05%
Share Statistics
EPS (TTM)-1.07
Shares Outstanding37,736,237
10 Day Avg. Volume367,558
30 Day Avg. Volume292,889
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-1.15
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FundingCash, cash equivalents, and investments totaled $78.5M, anticipated to fund operations into 2028.
PartnershipsNow partnered with the Drugs for Neglected Diseases initiative (DNDi), AN2 can leverage DNDi’s extensive clinical trial network and expertise in Chagas disease to rapidly advance the Phase 2 planning for AN2-502998.
Regulatory OutlookThe FDA is likely to accept Quality of Life measures as an efficacy endpoint, which is beneficial for the drug's approval process.
Bears Say
Clinical TrialsThe final shoe has dropped for AN2 Therapeutics' epetraborole program in refractory MAC lung disease, as the EBO-301 Ph.3 study missed the primary endpoint.
Efficacy ResultsThe culture conversion results for epetraborole were disappointing, although not unexpected.
Study OutcomesUnfortunately, the truncated EBO-301 Ph.3 study missed the primary endpoint and was unable to confirm the clinical efficacy observed in the Ph.2 portion.
AN2 Therapeutics, Inc. News
ANTX FAQ
What was AN2 Therapeutics, Inc.’s price range in the past 12 months?
AN2 Therapeutics, Inc. lowest stock price was $1.00 and its highest was $7.19 in the past 12 months.
What is AN2 Therapeutics, Inc.’s market cap?
AN2 Therapeutics, Inc.’s market cap is $127.17M.
When is AN2 Therapeutics, Inc.’s upcoming earnings report date?
AN2 Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 16 days.
How were AN2 Therapeutics, Inc.’s earnings last quarter?
AN2 Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.06.
Is AN2 Therapeutics, Inc. overvalued?
According to Wall Street analysts AN2 Therapeutics, Inc.’s price is currently Overvalued.
Does AN2 Therapeutics, Inc. pay dividends?
AN2 Therapeutics, Inc. pays a Quarterly dividend of $0.656 which represents an annual dividend yield of 17.05%. See more information on AN2 Therapeutics, Inc. dividends here
What is AN2 Therapeutics, Inc.’s EPS estimate?
AN2 Therapeutics, Inc.’s EPS estimate is -0.2.
How many shares outstanding does AN2 Therapeutics, Inc. have?
AN2 Therapeutics, Inc. has 37,736,237 shares outstanding.
What happened to AN2 Therapeutics, Inc.’s price movement after its last earnings report?
AN2 Therapeutics, Inc. reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went up 6.985%.
Which hedge fund is a major shareholder of AN2 Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ANTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AN2 Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ANTX Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 533.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
183.19%
12-Months-Change
Fundamentals
Return on Equity
-53.52%
Trailing 12-Months
Asset Growth
7.72%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Technical Analysis
Minerva Neurosciences
―
Anavex Life Sciences
―
Voyager Therapeutics
―
AC Immune SA
―
Neumora Therapeutics, Inc.
―
Ownership Overview
14.95% Insiders
3.41% Mutual Funds
38.38% Other Institutional Investors
36.19% Public Companies and
Individual Investors